AAOI, CMPR and WISA among mid-day movers
Seeking Alpha News (Mon, 27-Mar 1:06 PM ET)
NBRV, JNCE and ALIM among healthcare movers
Seeking Alpha News (Mon, 27-Mar 10:47 AM ET)
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
Globe Newswire (Mon, 27-Mar 8:00 AM ET)
Globe Newswire (Fri, 24-Mar 4:05 PM ET)
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
Globe Newswire (Mon, 27-Feb 8:00 AM ET)
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN
Globe Newswire (Wed, 22-Feb 8:00 AM ET)
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
Globe Newswire (Mon, 9-Jan 8:00 AM ET)
Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.
Alimera Sciences trades on the NASDAQ stock market under the symbol ALIM.
As of March 27, 2023, ALIM stock price climbed to $1.86 with 390,793 million shares trading.
ALIM has a market cap of $13.04 million. This is considered a Sub-Micro Cap stock.
Last quarter Alimera Sciences reported $14 million in Revenue and -$.75 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.35.
In the last 3 years, ALIM stock traded as high as $12.25 and as low as $1.30.
The top ETF exchange traded funds that ALIM belongs to (by Net Assets): VTI, VXF, IWC.
ALIM has underperformed the market in the last year with a return of -68.0%, while the SPY ETF lost -10.6%. In the last 3 month period, ALIM fell short of the market, returning -14.7%, while SPY returned +3.9%. However, in the most recent 2 weeks ALIM has outperformed the stock market by returning +5.1%, while SPY returned +3.1%.
ALIM support price is $1.23 and resistance is $1.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALIM stock will trade within this expected range on the day.